What Information Does US FDA Need For Stealth’s Elamipretide After CRL?

 
• By Sue Sutter
  
Door open, door closed
The FDA's complete response letter shut the door to regular approval, but opened the door to accelerated approval. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Complete Response Letters

More from Product Reviews